Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01406873 · ClinicalTrials.gov registry record · Phase 2
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01406873 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 42 participants.
The verdict
NCT01406873, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effects of mexiletine treatment for 6 months on ambulation, myotonia, muscle function and strength, pain, gastrointestinal functioning, cardiac conduction, and quality of life in myotonic dystrophy type 1 (DM1).
Interventions
- DRUG Placebo
- DRUG Mexiletine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01406873
The ClinicalTrials.gov registry entry for NCT01406873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01406873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01406873 about?
NCT01406873 is a clinical study titled "Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1". The purpose of this study is to investigate the effects of mexiletine treatment for 6 months on ambulation, myotonia, muscle function and strength, pain, gastrointestinal functioning, cardiac conduction, and quality of life in myotonic dystrophy type 1 (DM1).
What is the current status of trial NCT01406873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2011-06. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01406873?
The interventions under investigation include: Placebo (DRUG), Mexiletine (DRUG).
Who is sponsoring clinical trial NCT01406873?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.